Results 261 to 270 of about 84,355 (327)
What is your diagnosis? Fine‐needle aspirate from a subcutaneous preputial mass in a ferret
Veterinary Clinical Pathology, EarlyView.
Caitlyn F. Connor+5 more
wiley +1 more source
Ectopic thyroid carcinoma in the left atrium in a horse
Summary A 25‐year‐old Irish sport horse was presented for investigation of a 7‐day history of apathy and lethargy. Clinical examination revealed tachycardia, tachypnoea, distended, pulsating jugular veins and ventral oedema. Serum biochemistry showed azotaemia.
N. Wolf+4 more
wiley +1 more source
Combination of JAKi and HDACi Exerts Antiangiogenic Potential in Cutaneous T-Cell Lymphoma. [PDF]
Karagianni F+6 more
europepmc +1 more source
Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology
Abstract The peripheral T‐cell lymphomas (PTCL) are the only disease for which four histone deacetylase (HDAC) inhibitors have been approved globally as single agents. Although it is not clear why the PTCL exhibit such a vulnerability to these drugs, understanding the biological basis for this activity is essential.
Ariana Sabzevari+7 more
wiley +1 more source
Collisional variant of CD8+ mycosis fungoides and indolent CD8+ lymphoid proliferation
Adriana Lopez, MD+3 more
doaj
Cancer treatment and survivorship statistics, 2025
Abstract The number of people living with a history of cancer in the United States continues to rise because of the growth and aging of the population as well as improved survival through advances in early detection and treatment. To assist the public health community serve the needs of these survivors, the American Cancer Society and the National ...
Nikita Sandeep Wagle+9 more
wiley +1 more source
Spatial cell graph analysis reveals skin tissue organization characteristic for cutaneous T cell lymphoma. [PDF]
Sarkar S+6 more
europepmc +1 more source
Abstract Background Immune checkpoint inhibitors can be coadministered as a fixed‐ratio combination (FRC) or administered as sequential infusions (ASI). Two randomized, open‐label trials compared nivolumab + ipilimumab as a FRC versus ASI in patients with melanoma or renal cell carcinoma.
Alexander M. Menzies+19 more
wiley +1 more source